Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report released on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The stock has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.